Actively Recruiting
Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma
Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-04-14
60
Participants Needed
1
Research Sites
466 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate a new diagnostic imaging test, positron emission tomography (PET), with a different radioactive form of iodine called iodine-124. This form is able to accurately measure the amount of radioactive iodine uptake in the cancer. If the new test determines sufficient radioiodine uptake in the cancer, treatment will continue as usual. However, if the new test shows only low radioiodine uptake, a decision may be made that the benefit from radioiodine therapy is insufficient and that another form of therapy is preferred.
CONDITIONS
Official Title
Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults with thyroid carcinoma confirmed by pathology
- Adults who have undergone total thyroidectomy
- Adults with metastatic disease or suspicion of metastatic disease, or under protocol for re-induction therapy for 131I uptake
- Planning to receive 131I therapy if persistent radioiodine-avid metastases are present
- Measurable disease documented within the previous six months by ultrasonography, MRI, FDG PET/CT, or CT scanning
You will not qualify if you...
- Under 18 years of age
- Pregnant patients
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Actively Recruiting
Research Team
R
Ravinder Grewal, MD
CONTACT
S
Steven Larson, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here